CG Oncology (CGON) on Monday reported durable long-term outcomes from its phase 3 Bond-003 trial evaluating cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer, or NMIBC, unresponsive to Bacillus Calmette Guerin.
In Cohort C, 75.5% of patients achieved a complete response at any point during the study. At 24 months, 42.3% remained in complete response by Kaplan-Meier estimate, with 97.3% free from progression to muscle-invasive disease and 91.6% of initial responders remaining cystectomy-free.
Early results from Cohort P, in patients with BCG-unresponsive Ta/T1 disease without carcinoma in situ, showed a 90.5% high-grade recurrence-free survival rate at both three and nine months. Treatment was well-tolerated with no grade 3 or higher treatment-related adverse events reported.
The company is continuing to evaluate the therapy for potential regulatory submission.
Shares of CG Oncology rose 34% in recent trading activity.
Price: 30.06, Change: +7.69, Percent Change: +34.38
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。